Navigation Links
Cell Therapeutics Exercises Its Option to Sell Interest in Zevalin Joint Venture to Spectrum Pharmaceuticals for $18 Million
Date:2/20/2009

d by health care professionals qualified by training and experience in the safe use of radionuclides.

Patients and healthcare professionals can visit www.zevalin.com for more information.

About Non-Hodgkin's Lymphoma

Non-Hodgkin's lymphoma (NHL) is caused by the abnormal proliferation of white blood cells and normally spreads through the lymphatic system, a system of vessels that drains fluid from the body. NHL can be broadly classified into two main forms - aggressive NHL, a rapidly spreading acute form of the disease, and indolent NHL, which progresses more slowly. According to the National Cancer Institute's SEER database there were nearly 400,000 people in the U.S. with NHL in 2004. The American Cancer Society estimates that in the United States 66,120 people are expected to be diagnosed with NHL in 2008. Additionally, approximately 19,160 are expected to die from this disease in 2008.

About Cell Therapeutics, Inc.

Headquartered in Seattle, CTI is a biopharmaceutical company committed to developing an integrated portfolio of oncology products aimed at making cancer more treatable. For additional information, please visit www.celltherapeutics.com.

This press release includes forward-looking statements that involve a number of risks and uncertainties, the outcome of which could materially and/or adversely affect actual future results. Specifically, the risks and uncertainties that could affect the development of Zevalin include risks associated with preclinical and clinical developments in the biopharmaceutical industry in general and with Zevalin in particular including, without limitation, the potential for Zevalin FIT data to be acceptable to the FDA for this expanded indication or any other indication, the determinations by regulatory,
'/>"/>

SOURCE Cell Therapeutics, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related biology technology :

1. Vicus Therapeutics to Present at the 234th American Chemical Society National Meeting in Boston, MA
2. DJO Incorporateds Pending Merger With ReAble Therapeutics Clears U.S. Antitrust Review
3. PeriCor Therapeutics Announces Closing of Licensing Agreement for Acadesine with Schering-Plough Corporation
4. Systems Medicine (SM), a Subsidiary of Cell Therapeutics, Inc. (CTI), Announces Execution of CRADA with NCI/NIH to Develop Potential Cancer Treatments Targeting the Insulin Growth Factor (IGF) Pathway
5. Amsterdam Molecular Therapeutics to Release H1 2007 Results on August 29, 2007
6. Nektar Therapeutics Appoints Tim Harkness as Chief Financial Officer
7. ExonHit Therapeutics: Allergan and ExonHits First Collaboration Compound to Begin Human Clinical Trials
8. Cell Therapeutics, Inc. Takes Corrective Actions in Response to Nasdaq Determination
9. Amsterdam Molecular Therapeutics Reports Half Year Results 2007
10. Nektar Therapeutics Appoints Lutz Lingnau as New Board Member
11. Anesiva Grants Specific-Use License of Its Needle-Free Drug Delivery Technology to Particle Therapeutics for Diabetes Drug
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/30/2014)... and PARIS , July 30, 2014 ... SAN and NYSE: SNY) today announced that the Companies ... (FDA) rare pediatric disease priority review voucher in connection ...  The priority review voucher entitles the holder to designate ... expedited 6-month review from the filing date instead of ...
(Date:7/30/2014)... July 30, 2014  Decision Resources Group finds ... directors in the United States ... market penetration will be the level of savings ... the expected lower cost to patients. Payers plan ... meet their pricing expectations in order to encourage ...
(Date:7/30/2014)... Chicago Bears are excited to announce the team,s partnership ... effort to raise awareness of skin cancer. Through this ... skin cancer screenings at a preseason fan event on ... me™ is an educational campaign designed to inform the public, ... cancer, and encourages people to get screened by a ...
(Date:7/30/2014)... While administrative claims and other data ... a relatively long period of time, there has ... of these ‘big data’ for comparisons of interventions ... powerful computer technology with the plethora of data ... significant promise for identifying optimal interventions for specific ...
Breaking Biology Technology:Regeneron and Sanofi Announce Plan to Use Priority Review Voucher For Alirocumab U.S. FDA Submission 2Regeneron and Sanofi Announce Plan to Use Priority Review Voucher For Alirocumab U.S. FDA Submission 3Regeneron and Sanofi Announce Plan to Use Priority Review Voucher For Alirocumab U.S. FDA Submission 4Regeneron and Sanofi Announce Plan to Use Priority Review Voucher For Alirocumab U.S. FDA Submission 5Regeneron and Sanofi Announce Plan to Use Priority Review Voucher For Alirocumab U.S. FDA Submission 6Surveyed U.S. Payers Expect Cost Savings to MCOs and Patients to be the Strongest Drivers of Biosimilar Uptake 2Surveyed U.S. Payers Expect Cost Savings to MCOs and Patients to be the Strongest Drivers of Biosimilar Uptake 3Chicago Bears Join the American Academy of Dermatology in Fight against Skin Cancer 2Chicago Bears Join the American Academy of Dermatology in Fight against Skin Cancer 3Chicago Bears Join the American Academy of Dermatology in Fight against Skin Cancer 4Leveraging ‘Big Data’ - Methodological Considerations in Health Services Research, New Webinar Hosted by Xtalks 2
... on the Legislature and the Doyle administration Wednesday to ... fund would use existing information technology dollars allocated to ... portion of the funds for enterprise information management system ... this fund. , ,This fund is long overdue, Kanavas ...
... In a column I wrote last year, I alluded to ... global. In fact, there are now 4,284 biotech companies in 25 ... , ,Moreover: , , The biotech industry has 622 publicly ... $16 billion in R&D in 2001. , , The industry ...
... Forbes magazine released its annual rankings of best cities ... spoke in Madison about the rise of small and ... conclusion was simple: The Information Age has made it ... are settling down in smaller, more livable cities. , ...
Cached Biology Technology:In Globalizing Biotech, Midwest Must Differentiate From Pack 2In Globalizing Biotech, Midwest Must Differentiate From Pack 3In Globalizing Biotech, Midwest Must Differentiate From Pack 4Forbes rating is more than kudos for Madison its a reflection on Wisconsin and the Midwest 2Forbes rating is more than kudos for Madison its a reflection on Wisconsin and the Midwest 3
(Date:7/30/2014)... ranges and a changing climate threaten some of ... and so conservationists establish seed collections to save ... hopes of preserving some genetic diversity., For decades, ... models that offer a one-size-fits-all approach for how ... 50 seed samples regardless of species, pollination mode, ...
(Date:7/30/2014)... CHAMPAIGN, Ill. Scientists are searching through a massive ... more than 50 years ago, and the effort is ... world they inhabited. , When the collection is fully ... will be the largest unbiased Dominican amber collection in ... most striking discovery thus far is that of a ...
(Date:7/30/2014)... subject of major interest in neuroscience. A large ... distinct stages of Wallerian degeneration: transcription factor activation, ... gene expression responses in the distal segment of ... known, differences in gene expression between the proximal ... and co-workers from Nantong University, China used microarrays ...
Breaking Biology News(10 mins):Saving seeds the right way can save the world's plants 2Decades-old amber collection offers new views of a lost world 2
... Jewish Health have discovered a type of cell that may ... lupus, multiple sclerosis and rheumatoid arthritis strike women more frequently ... make autoantibodies, which bind to and attack the body,s own ... of the journal Blood , that they found higher ...
... programmed cell death - a process by which cells ... in termites. And it appears this regression may be ... defensive organs, according to Kouhei Toga and Kiyoto Maekawa ... the University of Tokyo, in Japan. Their findings have ...
... tropics make it tough for farmers to keep their crops ... seems to defy efforts to control its population. Some farmers ... the weevils but they have not been successful. Since the ... the immature stages. The sweetpotato weevil is a year round ...
Cached Biology News:B-cell discovery suggests why women suffer more autoimmune disease 2Cells die so defensive organs can live 2Biocontrol of sweetpotato weevils 2
... reagent for Virus isolation ... unique water insoluble Elastomeric ... and chaotropes; Engineered to ... viruses while preserving infectivity; ...
AMAP Multi Site-directed Mutagenesis Kit Research Focus: other Storage Temperature: -20C Shipping Temperature: dry ice...
Umbilical cord blood mesenchymal stem cells, For immunohistochemistry (IHC) Cell Chip with Human Umbilical Cord Blood Progenitor Cells...
Umbilical cord blood mononuclear cells, For immunohistochemistry (IHC) Cell Chip with Human Umbilical Cord Blood MNCs and T Cells...
Biology Products: